264 related articles for article (PubMed ID: 27955980)
1. The metabolism of glucocerebrosides - From 1965 to the present.
Futerman AH; Platt FM
Mol Genet Metab; 2017; 120(1-2):22-26. PubMed ID: 27955980
[TBL] [Abstract][Full Text] [Related]
2. Ubiquitous transgene expression of the glucosylceramide-synthesizing enzyme accelerates glucosylceramide accumulation and storage cells in a Gaucher disease mouse model.
Barnes S; Xu YH; Zhang W; Liou B; Setchell KD; Bao L; Grabowski GA; Sun Y
PLoS One; 2014; 9(12):e116023. PubMed ID: 25551612
[TBL] [Abstract][Full Text] [Related]
3. Improved management of lysosomal glucosylceramide levels in a mouse model of type 1 Gaucher disease using enzyme and substrate reduction therapy.
Marshall J; McEachern KA; Chuang WL; Hutto E; Siegel CS; Shayman JA; Grabowski GA; Scheule RK; Copeland DP; Cheng SH
J Inherit Metab Dis; 2010 Jun; 33(3):281-9. PubMed ID: 20336375
[TBL] [Abstract][Full Text] [Related]
4. Complement drives glucosylceramide accumulation and tissue inflammation in Gaucher disease.
Pandey MK; Burrow TA; Rani R; Martin LJ; Witte D; Setchell KD; Mckay MA; Magnusen AF; Zhang W; Liou B; Köhl J; Grabowski GA
Nature; 2017 Mar; 543(7643):108-112. PubMed ID: 28225753
[TBL] [Abstract][Full Text] [Related]
5. Glucosylceramide and Glucosylsphingosine Quantitation by Liquid Chromatography-Tandem Mass Spectrometry to Enable In Vivo Preclinical Studies of Neuronopathic Gaucher Disease.
Hamler R; Brignol N; Clark SW; Morrison S; Dungan LB; Chang HH; Khanna R; Frascella M; Valenzano KJ; Benjamin ER; Boyd RE
Anal Chem; 2017 Aug; 89(16):8288-8295. PubMed ID: 28686011
[TBL] [Abstract][Full Text] [Related]
6. Biochemical response to substrate reduction therapy versus enzyme replacement therapy in Gaucher disease type 1 patients.
Smid BE; Ferraz MJ; Verhoek M; Mirzaian M; Wisse P; Overkleeft HS; Hollak CE; Aerts JM
Orphanet J Rare Dis; 2016 Mar; 11():28. PubMed ID: 27008851
[TBL] [Abstract][Full Text] [Related]
7. Phosphatidylcholine synthesis is elevated in neuronal models of Gaucher disease due to direct activation of CTP:phosphocholine cytidylyltransferase by glucosylceramide.
Bodennec J; Pelled D; Riebeling C; Trajkovic S; Futerman AH
FASEB J; 2002 Nov; 16(13):1814-6. PubMed ID: 12223447
[TBL] [Abstract][Full Text] [Related]
8. Neuronal forms of Gaucher disease.
Vitner EB; Futerman AH
Handb Exp Pharmacol; 2013; (216):405-19. PubMed ID: 23563668
[TBL] [Abstract][Full Text] [Related]
9. Gaucher disease: Progress and ongoing challenges.
Mistry PK; Lopez G; Schiffmann R; Barton NW; Weinreb NJ; Sidransky E
Mol Genet Metab; 2017; 120(1-2):8-21. PubMed ID: 27916601
[TBL] [Abstract][Full Text] [Related]
10. Acid beta-glucosidase: insights from structural analysis and relevance to Gaucher disease therapy.
Kacher Y; Brumshtein B; Boldin-Adamsky S; Toker L; Shainskaya A; Silman I; Sussman JL; Futerman AH
Biol Chem; 2008 Nov; 389(11):1361-9. PubMed ID: 18783340
[TBL] [Abstract][Full Text] [Related]
11. In vitro accumulation of glucocerebroside in neuroblastoma cells: a model for study of Gaucher disease pathobiology.
Prence EM; Chaturvedi P; Newburg DS
J Neurosci Res; 1996 Feb; 43(3):365-71. PubMed ID: 8714525
[TBL] [Abstract][Full Text] [Related]
12. Cellular and biochemical response to chaperone versus substrate reduction therapies in neuropathic Gaucher disease.
Ivanova MM; Dao J; Kasaci N; Adewale B; Nazari S; Noll L; Fikry J; Sanati AH; Goker-Alpan O
PLoS One; 2021; 16(10):e0247211. PubMed ID: 34695170
[TBL] [Abstract][Full Text] [Related]
13. Lipids regulate the hydrolysis of membrane bound glucosylceramide by lysosomal β-glucocerebrosidase.
Abdul-Hammed M; Breiden B; Schwarzmann G; Sandhoff K
J Lipid Res; 2017 Mar; 58(3):563-577. PubMed ID: 28126847
[TBL] [Abstract][Full Text] [Related]
14. Emerging therapeutic targets for Gaucher disease.
Vitner EB; Vardi A; Cox TM; Futerman AH
Expert Opin Ther Targets; 2015 Mar; 19(3):321-34. PubMed ID: 25416676
[TBL] [Abstract][Full Text] [Related]
15. An evolutionary and structure-based docking model for glucocerebrosidase-saposin C and glucocerebrosidase-substrate interactions - relevance for Gaucher disease.
Atrian S; López-Viñas E; Gómez-Puertas P; Chabás A; Vilageliu L; Grinberg D
Proteins; 2008 Feb; 70(3):882-91. PubMed ID: 17803231
[TBL] [Abstract][Full Text] [Related]
16. Interaction with ERp57 is required for progranulin protection against Type 2 Gaucher disease.
Liu Y; Zhao X; Jian J; Hasan S; Liu C
Biosci Trends; 2023 May; 17(2):126-135. PubMed ID: 36889696
[TBL] [Abstract][Full Text] [Related]
17. A 20-Year Longitudinal Study of Plasma Chitotriosidase Activity in Treated Gaucher Disease Type 1 and 3 Patients-A Qualitative and Quantitative Approach.
Szymańska-Rożek P; Czartoryska B; Kleinotiene G; Lipiński P; Tylki-Szymańska A; Ługowska A
Biomolecules; 2023 Feb; 13(3):. PubMed ID: 36979371
[TBL] [Abstract][Full Text] [Related]
18. Velaglucerase alfa, a human recombinant glucocerebrosidase enzyme replacement therapy for type 1 Gaucher disease.
Pastores GM
Curr Opin Investig Drugs; 2010 Apr; 11(4):472-8. PubMed ID: 20336596
[TBL] [Abstract][Full Text] [Related]
19. Ex vivo and in vivo effects of isofagomine on acid β-glucosidase variants and substrate levels in Gaucher disease.
Sun Y; Liou B; Xu YH; Quinn B; Zhang W; Hamler R; Setchell KD; Grabowski GA
J Biol Chem; 2012 Feb; 287(6):4275-87. PubMed ID: 22167193
[TBL] [Abstract][Full Text] [Related]
20. Value of plasma chitotriosidase to assess non-neuronopathic Gaucher disease severity and progression in the era of enzyme replacement therapy.
van Dussen L; Hendriks EJ; Groener JE; Boot RG; Hollak CE; Aerts JM
J Inherit Metab Dis; 2014 Nov; 37(6):991-1001. PubMed ID: 24831585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]